Skip to main content
. 2016 Mar 17;7(24):35768–35775. doi: 10.18632/oncotarget.8157

Figure 3. Sensitivity analysis of the pooled ORs and 95%CIs for TIM-3 +4259T/G polymorphism.

Figure 3